SBIR/STTR Research Award
Human PSMA MAb Radioimmunotherapy for Prostate Cancer
Award amount
$3,830,890Program and phase
SBIR · Phase IIAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROGENICS PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- YLYKVRPCTCR3
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
Prostate cancer is the most common cancer of men in the United States with approximately 189,000 new cases and 30,000 deaths in 2002. Recurrent disease can be controlled temporarily with androgen ablation. However, almost all prostate carcinomas eventuall
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- PSMA Antibody-Drug Conjugate for Prostate Cancer Therapy
- PSMA-VRP vaccine for prostate cancer
- Broadly Neutralizing MAbs against Hepatitis C Virus
- Novel small-molecule inhibitors of HIV-1 Vif
- Broadly Inhibitory MAbs Targeting Hepatitis C Virus Receptors
Research funding history
39 SBIR/STTR records share this UEI (1990–2007). Reported award amounts total $29,853,777. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services